Oscar Izeboud, PhD
CEO & Executive Director25 years of experience in biotech, including 14 years in investment banking. Oscar joined Scenic in July 2020 as CEO and Board Director.
He is involved as NED with a number of other biotech companies across Europe and co-owner of Kaapse Brouwers in Rotterdam.
Jens Würthner, MD, PhD
CMO20+ years of clinical development experience from research institutions as well as big pharma and biotech companies including Novartis, GlaxoSmithKline, AstraZeneca, and most recently
ADC Therapeutics. Jens joined Scenic in 2022 as Chief Medical Officer.
Margot Hoppe
VP Legal30+ years of experience in (corporate) legal affairs, having worked for various biotechnology and life sciences companies including Kiadis Pharma, Gist-Brocades and Royal DSM.
Annette Galler, PhD
VP Development20 years of experience in pharmaceutical industry and biotech encompassing successful global drug development, marketing and launch at e.g., Merck KGaA, Wyeth Pharma and Boehringer Ingelheim.
Annette started at Scenic Biotech in May 2022 and joined the Leadership Team as VP Portfolio Strategy in May 2023.
Carola Jongerius
Head people & culture25+ experience in Human Resources and coaching. First 15 years in corporate companies such as Andersen, Deloitte and as a consultant with the Human Capital group. The last 10 years specialized
in supporting start up and scale ups to professionalize the Human Resource function. Carola joined Scenic in 2019 as head of People and Culture.
Peter Ros, RA
VP Finance & Operations20+ years of global finance and accounting experience in biotech start- and scale up companies including Genmab and most recently LAVA Therapeutics. Peter started his career at PwC.Peter joined Scenic in October 2024 as VP Finance & Operations.
Philippe Dro
Chairman of the BoardPhilippe has fulfilled leading roles in multiple biotech and medtech companies, including Themis Bioscience (acquired by Merck), GlycoVaxyn (acquired by GSK), Endoart (acquired by Allergan) and Axovan (acquired by Actelion).
Philippe serves on the Board of Luciole.
Oscar Izeboud, PhD
CEO & Executive Director25 years of experience in biotech, including 14 years in investment banking. Oscar joined Scenic in July 2020 as CEO and Board Director.
He is involved as NED with a number of other biotech companies across Europe and co-owner of Kaapse Brouwers in Rotterdam.
Ben Machielse, PhD
Independent Non-executive DirectorBen brings over 25 years of industry experience across all stages of drug development, including rare disease indications like Niemann-Pick Disease. He served as CEO of Vtesse and oversaw the completion of the pivotal study as well as the subsequent acquisition by Sucampo Pharmaceuticals in 2017.
Before this, Ben was COO at Omthera where he played a crucial role in the development and approval of the company’s candidate for hypertriglyceridemia, Omthera’s IPO and eventual acquisition by AstraZeneca. Earlier in his career, Ben held executive positions in development, quality and operations at MedImmune, Xoma Corporation and Centocor BV. He also currently serves as chairman of the board at Mosanna Therapeutics.
Edward van Wezel
Non-executive DirectorEdward is Founder and Managing Partner at BioGeneration Ventures (BGV) and combines over 20 years of experience in venture capital, pharma licensing, drug development and translational research.
He was founding investor and board member of Acerta Pharma (acquired by Astra Zeneca for $7B) and currently serves on the boards of several BGV portfolio companies.
Simone Botti, PhD
Non-Executive DirectorSimone is a Partner at Inkef and brings with him 20 years of experience across venture capital and startup creation. Before joining INKEF Simone was CEO of Metabomed, a cancer metabolism company he co-founded while he was Head of the Israel Bioincubator Fund at M Ventures.
Simone accumulated his company building experience while at M Ventures, where he established and led several healthcare startups. During that time Simone also served as a Board Member of IATI, the Israel Advanced Technology Industries association. Previously, he was Vice President Business Development at RAD Biomed Accelerator, one of Israel’s leading life science incubators. Simone did his PhD in Structural Biology and Neurobiology at the Weizmann Institute of Science, where he received the “Dov Elad” prize in Structural Biology.
Stéphane Verdood
Non-executive DirectorStéphane Verdood has an MBA and a Master’s degree in commercial engineering from the Catholic University of Leuven. Stéphane is a recognized venture capitalist.
He started his career with Arthur Andersen as information technology auditor. After having led the mergers and acquisitions division of Arthur Andersen in Belgium from 1989 to 1995, he founded and led Arthur Andersen’s business consulting division in Belgium and Luxembourg. He served on the European Board of Partners of Arthur Andersen. Since October 2000, before he joined Vesalius Biocapital, Stéphane has been active as a venture coach for early-stage companies. He was a founder and managing partner at Value4Growth, a specialized Life Science consulting firm supporting start-up companies in all aspects of company formation, product strategy and fund raising.Stéphane is a founding partner of Vesalius Biocapital Funds specialized in venture capital for European biotechnology companies. Since 2007 Vesalius has invested in more than 20 biotech companies. During his career he has worked in the US, Switzerland, France, the Netherlands, the UK and Portugal. Fund raising to set up Fund I in 2007 and Fund II in 2011.
Michael Wacker
Non-executive DirectorMichael is an experienced life science entrepreneur and General Partner at BioMedPartners. Michael serves on the board of directors of various portfolio companies.
In addition, he coaches start-ups in Switzerland for Innosuisse, the governmental commission of technology and innovation. Before joining BioMedPartners, Michael was founder and CSO of GlycoVaxyn (acquired by GSK) and chairman of Inositec (acquired by Vifor).
Stephan Christgau, PhD
Non-executive DirectorStephan is founding partner of the Nordic Life Science Venture fund, Eir Ventures. Prior to launching Eir Ventures, Stephan was part of setting up Novo Seeds, the early stage company creation and investment arm of Novo Holdings.
During his 12 years at Novo Seeds, he led creation and funding of more than 25 companies in Europe, with a particular focus on Scandinavia. Stephan has extensive operational experience from management and research scientist roles in European and US Biotech and holds a PhD in Protein Chemistry and immunology from UCSF.
Prof. Sebastian Nijman
Founder & Board ObserverCo-founder of Scenic Biotech, Haplogen, and Haplogen Genomics. Associate Professor at the University of Oxford.
Former member of the Ludwig Institute for Cancer Research in Oxford, principle investigator at CeMM, Vienna, and postdoc at the Broad Institute, Cambridge, MA.
Nick Dixon-Clegg
Board ObserverNick serves on the board of Scenic as an Observer, representing investor Oxford Science Enterprises, where he is a Partner. He brings experience from a career spent in investing and corporate finance.
Nick joined Oxford Sciences Enterprises from Valiance, a MedTech-focused venture capital firm. He was previously an investor at large cap buyout private equity firm Nordic Capital. Prior to that he began his career as an investment banker at Bank of America Merrill Lynch.
